Economic evaluations in bipolar disorder: a systematic review and critical appraisal

  title={Economic evaluations in bipolar disorder: a systematic review and critical appraisal},
  author={Anees Ahmed Abdul Pari and J. Simon and J. Wolstenholme and J. Geddes and G. Goodwin},
  journal={Bipolar Disorders},
  pages={557 - 582}
Bipolar disorder (BD) is a chronic illness and is one of the worldwide leading causes of disability. It is often a lifelong illness and incurs a substantial economic burden on the health care system, the patients, and society as a whole. However, there are few studies evaluating the economic impact of alternative strategies in the management of BD. 
Economic evaluations of non-pharmacological interventions and cost-of-illness studies in bipolar disorder: A systematic review.
It is suggested that non-pharmacological intervention for BD might be cost-effective and the number of EEs was relatively low and methodology was heterogenous and therefore encourage future research to widen the body of knowledge in this research field. Expand
Cost-Effectiveness of Treatment for Bipolar Disorders
This chapter focuses on a review the cost-effectiveness studies of bipolar disorder (BD) published in the past 10 years in order to present the main methodological issues related to economicExpand
Cost-Effectiveness Evaluations of Psychological Therapies for Schizophrenia and Bipolar Disorder: A Systematic Review
Most studies concluded psychological interventions for schizophrenia/BD are cost-effective, including CBT, although there was notable uncertainty. Expand
Is treatment for bipolar disorder more effective earlier in illness course? A comprehensive literature review
There is a first episode and early phase effect of bipolar disorder and findings provide evidence for the clinical utility of an early intervention approach in bipolar disorder to improve patient outcomes. Expand
Targets and outcomes of psychotherapies for mental disorders: an overview
  • P. Cuijpers
  • Medicine
  • World psychiatry : official journal of the World Psychiatric Association
  • 2019
The main types of targets and outcomes of psychotherapies are described, and a brief overview is provided of some of the main results of research on these types. Expand
The real world cost and health resource utilization associated to manic episodes: The MANACOR study.
Abstract Introduction Bipolar disorder is a relapsing-remitting condition affecting approximately 1–2% of the population. Even when the treatments available are effective, relapses are still veryExpand
The real world cost and health resource utilization associated to manic episodes: The MANACOR study.
The results show the high cost and burden associated with BD and the need to design more cost-efficient strategies in the prevention and management of manic relapses in order to avoid hospital admissions. Expand
Bipolar disorder: Prevalence, help-seeking and use of mental health care in England. Findings from the 2014 Adult Psychiatric Morbidity Survey.
Most people with BD had not received any specific treatment for the condition in the last year, while 1 in 7 had requested specific help but did not receive it. Expand
Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL)
Although not licensed for acute bipolar depression, lamotrigine has evidence for efficacy in trials and its use is recommended in guidelines. So far there had been no prospective health economicExpand
Characteristics of help-seeking behavior among bipolar disorder patients
Non-help-seekers were faced with more difficulties in their social functions and social interactions and were more likely to be older, divorced, or widowed, mostly illiterate or elementary education, more physically consulted in the past year, able to effective work or study, at a stable illness status. Expand


Economic evidence in affective disorders: a review
  • M. Löthgren
  • Political Science, Medicine
  • The European Journal of Health Economics
  • 2005
There is a fairly poor evidence base available on cost of substance abuse in Europe, where the most recent studies are performed in the middle of the 1990s, and cover only the major EuropeanExpand
Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode
Compared with olanzapine, the results suggest that quetiapine is cost effective as a maintenance treatment for bipolar depression. Expand
Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder
Community-based interventions for bipolar disorder were estimated to be more efficient than hospital-based services, each DALY averted costing between one and three times average gross national income. Expand
A model of the economic impact of a bipolar disorder screening program in primary care.
A 1-time screening program for bipolar disorder, when patients first present with a major depressive episode, can reduce health care costs to managed-care plans. Expand
Annual cost of managing bipolar disorder to the UK healthcare system.
The direct medical cost of managing bipolar disorder in the UK healthcare system is considerable and therapeutic strategies that optimize community-based management, prevention of recurrence and hospitalization could reduce the economic burden of this illness. Expand
Long-Term Prophylaxis in Bipolar Disorder
The available evidence for a range of pharmacological options is summarized, guidance on common issues in clinical management in line with current practice guidelines is provided, and gradual tapering of dose over weeks or months is recommended. Expand
Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder
Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder are made. Expand
Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder
A comparison of the total costs demonstrates that all of the monotherapy options and placebo are more costly than the combination treatment options, and the combination of lithium/quetiapine and olanzapine/lithium was superior in terms of serious side effects. Expand
Depressive and manic symptoms are not opposite poles in bipolar disorder
Depressive and manic symptoms are not opposite poles in bipolar disorder. Expand
Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial.
Divalproex maintenance treatment for bipolar disorder resulted in comparable medical costs, clinical and QOL outcomes compared with lithium. Expand